56 results on '"Maurel, J."'
Search Results
2. A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.
3. Retrospective analysis of surgery in metastatic GIST patients sensitive to imatinib: A Spanish Group for Research on Sarcoma (GEIS) study.
4. A phase I dose-finding study of sorafenib (S) in combination with gemcitabine (G) and radiotherapy (RT) in patients (pts) with unresectable pancreatic carcinoma (UPC): A GEMCAD study.
5. Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome.
6. Effect of the quality of the methodology on the relationship between progression-free survival (PFS) and overall survival (OS) in advanced colorectal cancer clinical trials.
7. Targeted therapy to EGFR and HER2 combined with gemcitabine in a novel human pancreatic orthotopic model.
8. MMP-7 serum levels as predictor or prognostic of cetuximab benefit in the treatment of advanced colorectal cancer: Results from a HCB-05 prospective trial.
9. BRCA1 mRNA expression and response in locally advanced esophageal cancer patients (p) treated with chemoradiotherapy.
10. Preoperative chemoradiotherapy (QRTP) and total mesorectal excision (TME) by laparoscopy (LPS) in rectal cancer (RC): Long-term outcomes.
11. Usefulness of PET/CT in the diagnosis of distant metastases of potentially operable gastric adenocarcinoma
12. Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial
13. Correlation between spiral CT and PET in patients with advanced GIST refractory to high-dose imatinib: A GEIS study
14. Phase II study with preoperative oxaliplatin (O), cisplatin (P), 5-fluorouracil (F) (OPF) and radiation (XRT) in patients with esophageal (ES), gastroesophageal (GE), and gastric (G) cancer
15. EGFR polymorphism and KRAS mutational status as predictors of resistance to anti-EGFR therapy in advanced colorectal cancer (ACRC): A GEMCAD study
16. Screening candidate targets by SAGE evaluation of rectal cancer transcriptome after chemoradiotherapy: Association of trefoil factor-family 3 (TFF3) expression with patients prognosis
17. Coexpression of matrix metalloproteinase-7 (MMP7) and phosphorylated insulin growth factor receptor I (pIGF-IR) as predictors of resistance to anti-EGFR therapy in advanced colorectal cancer (ACRC): A GEMCAD study
18. Multicenter randomized phase II study of chemoradiation (CRT) followed by surgery (S) and chemotherapy (CT) versus induction CT followed by CRT and S in high-risk rectal cancer: GCR-3 final efficacy and safety results
19. Serum IGFBP3, IGF-I, and MMP7 changes in advanced colorectal cancer (ACRC) patients (pts) treated with anti-EGFR therapy: A GEMCAD study
20. Randomized phase II study of dacarbazine plus gemcitabine versus DTIC alone in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study
21. A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC)
22. Phase I-II trial of imatinib (IM) and low-dose doxorubicin (DX) in patients (pts) with advanced gastrointestinal stromal tumors (GIST), refractory to high-dose IM: A GEIS Study
23. Correlation of matrilysin levels and IGF-1/IGFBP-3 ratio with acquired chemo-resistance in advanced colorectal cancer (ACRC)
24. EGFR polymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer (ACRC) treated with cetuximab and panitumumab
25. Pharmacodynamic study of soluble FAS (sFAS) and FASL (sFASL), in patients (pts) with advanced colorectal cancer (ACRC) after irinotecan and cetuximab treatment in third-line therapy: Results of HCB-05–01 trial
26. Standard-dose doxorubicin versus sequential dose-dense doxorubicin and ifosfamide in patients with untreated advanced soft tissue sarcoma (ASTS): A GEIS Study
27. Time dependence of critical deletions as prognostic factor for relapse-free survival (RFS) in localised GIST. A Spanish Group for Sarcoma Research (GEIS) study
28. Randomized phase II trial comparing two strategies in high-risk rectal cancer (RC): Chemoradiation (CRT) followed by total mesorectal excision (TME) and adjuvant chemotherapy (CT) or induction CT followed by CRT and TME— Preliminary results of the multicenter GCR-3 study
29. Optimized preclinical models for human pancreatic adenocarcinoma therapy research
30. A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component
31. Phase I trial of neoadjuvant chemoradiotherapy with capecitabine and weekly irinotecan followed by laparoscopic mesorectal excision
32. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
33. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial
34. Serum matrilysin (MMP7) levels are associated with progression, in curatively resected colorectal cancer (CRC) patients
35. Role of metalloproteinase-7 in oxaliplatin acquired resistance in colorectal cancer cell lines
36. Phase I trial of gefitinib with concurrent radiotherapy and fixed dose-rate gemcitabine infusion, in locally advanced pancreatic cancer
37. Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC)
38. Preliminary results of a randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (CapeOx) vs. oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC)
39. TOMOX compared to FOLFOX4 as first-line treatment in patients (pts) with advanced colorectal cancer (ACRC): Results of a multicenter randomized phase II trial
40. Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of the first 400 patients in a randomized phase III trial (EPIC)
41. Phase I trial of cisplatin (CDDP), docetaxel (TXT) and CPT-11 in patients (p) with advanced esophagogastric cancer: Feasibility and activity related to XPD and UGT1A1 gene polymorphisms
42. Laparoscopic-assisted mesorectal excision (LAME) after neoadjuvant chemoradiotherapy (CRT)
43. TOMOX compared to FOLFOX4 as first-line treatment in patients (pts) with advanced colorectal cancer (ACRC): Preliminary results of a multicenter randomized phase II trial
44. Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS)
45. FASs/FASLs ratio: A marker of chemoresistance in advanced colorectal cancer (CRC)
46. A phase I study of radiation therapy (RT) with concurrent oxaliplatin (OXL), cisplatin (P) and protacted infusion 5-fluorouracil (FU) for locally advanced esophageal (ES) or gastroesophageal (GEJ) carcinoma
47. Prognostic value of pathologic variables and mutations type in patients with complete surgical resection of gastrointestinal stromal tumors (GIST). A GEIS study
48. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase ii study of the spanish group for research on sarcomas.
49. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
50. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors...
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.